GT BIOPHARMA, INC. Amortization of Debt Issuance Costs and Discounts
GT BIOPHARMA, INC. (GTBP) reported Amortization of Debt Issuance Costs and Discounts of $1.14 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2020-03-27
- GT BIOPHARMA, INC. amortization of debt issuance costs and discounts for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. amortization of debt issuance costs and discounts for the quarter ending 2019-09-30 was $0.00.
- GT BIOPHARMA, INC. amortization of debt issuance costs and discounts for the quarter ending 2019-06-30 was $1.14M.
- GT BIOPHARMA, INC. amortization of debt issuance costs and discounts for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. amortization of debt issuance costs and discounts for fiscal 2019 was $1.14M, a 158.50% increase from fiscal 2018.
- GT BIOPHARMA, INC. amortization of debt issuance costs and discounts for fiscal 2018 was $441.00K, a 79.93% decline from fiscal 2017.
- GT BIOPHARMA, INC. amortization of debt issuance costs and discounts for fiscal 2017 was $2.20M, a 34.62% increase from fiscal 2016.
- GT BIOPHARMA, INC. amortization of debt issuance costs and discounts for fiscal 2016 was $1.63M, a 83.41% decline from fiscal 2015.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $0.00 derived: sum of 2 quarters · filed 2020-03-27 | $1.14M derived: sum of 3 quarters · filed 2020-03-27 | $1.14M 10-K · filed 2020-03-27 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $1.14M derived: sum of 2 quarters · filed 2019-11-14 | $1.14M 10-Q · filed 2019-11-14 | $1.58M derived: sum of 4 quarters · filed 2020-03-27 |
| 2019-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $1.14M 10-Q · filed 2019-08-14 | $1.58M derived: sum of 3 quarters · filed 2020-03-27 | $1.58M derived: sum of 4 quarters · filed 2020-03-27 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-15 | $441.00K derived: sum of 2 quarters · filed 2020-03-27 | $441.00K derived: sum of 3 quarters · filed 2020-03-27 | $175.00K derived: sum of 4 quarters · filed 2020-03-27 |
| 2018-12-31 | $441.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $441.00K derived: sum of 2 quarters · filed 2020-03-27 | $175.00K derived: sum of 3 quarters · filed 2020-03-27 | $441.00K 10-K · filed 2020-03-27 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$266.00K derived: sum of 2 quarters · filed 2019-11-14 | $0.00 10-Q · filed 2019-11-14 | $0.00 derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | -$266.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $0.00 10-Q · filed 2019-08-14 | $0.00 derived: sum of 3 quarters · filed 2019-08-14 | $0.00 derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $266.00K 10-Q · filed 2019-05-15 | $266.00K derived: sum of 2 quarters · filed 2019-05-15 | $266.00K derived: sum of 3 quarters · filed 2019-05-15 | $266.00K derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $0.00 derived: sum of 2 quarters · filed 2019-03-29 | $0.00 derived: sum of 3 quarters · filed 2019-03-29 | $2.20M 10-K · filed 2019-03-29 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $2.20M 10-Q · filed 2018-11-14 | $2.13M derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $2.20M 10-Q · filed 2018-08-14 | $2.13M derived: sum of 3 quarters · filed 2018-08-14 | $2.33M derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | $2.20M 10-Q · filed 2018-05-15 | $2.13M derived: sum of 2 quarters · filed 2018-05-15 | $2.33M derived: sum of 3 quarters · filed 2018-05-15 | $3.36M derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | -$65.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $128.00K derived: sum of 2 quarters · filed 2018-03-01 | $1.16M derived: sum of 3 quarters · filed 2018-03-01 | $1.63M 10-K · filed 2018-03-01 |
| 2016-09-30 | $193.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-02-28 | $1.22M derived: sum of 2 quarters · filed 2018-02-28 | $1.70M 10-Q/A · filed 2018-02-28 | $3.82M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $1.03M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-02-28 | $1.50M 10-Q/A · filed 2018-02-28 | $3.63M derived: sum of 3 quarters · filed 2018-02-28 | $4.46M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $473.00K 10-Q/A · filed 2018-02-28 | $2.60M derived: sum of 2 quarters · filed 2018-02-28 | $3.43M derived: sum of 3 quarters · filed 2018-02-28 | $3.43M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $2.12M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2018-02-28 | $2.96M derived: sum of 2 quarters · filed 2018-02-28 | $2.96M derived: sum of 3 quarters · filed 2018-02-28 | $9.84M 10-K/A · filed 2018-02-28 |
| 2015-09-30 | $837.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-02-28 | $836.00K derived: sum of 2 quarters · filed 2018-02-28 | $7.72M 10-Q/A · filed 2018-02-28 | $8.83M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-06-30 | -$1.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-02-28 | $6.88M 10-Q/A · filed 2018-02-28 | $7.99M derived: sum of 3 quarters · filed 2018-02-28 | $9.63M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-03-31 | $6.88M 10-Q/A · filed 2018-02-28 | $8.00M derived: sum of 2 quarters · filed 2018-02-28 | $9.63M derived: sum of 3 quarters · filed 2018-02-28 | $9.64M derived: sum of 4 quarters · filed 2018-02-28 |
| 2014-12-31 | $1.11M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-02-28 | $2.75M derived: sum of 2 quarters · filed 2018-02-28 | $2.76M derived: sum of 3 quarters · filed 2018-02-28 | $2.76M 10-K/A · filed 2018-02-28 |
| 2014-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $1.65M derived: sum of 2 quarters · filed 2015-11-13 | $1.65M 10-Q · filed 2015-11-13 | $1.51M derived: sum of 4 quarters · filed 2015-11-13 |
| 2014-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $19.00K 10-Q · filed 2015-08-14 | -$120.00K derived: sum of 3 quarters · filed 2015-08-14 | -$120.00K derived: sum of 4 quarters · filed 2015-08-14 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-14 | -$139.00K derived: sum of 2 quarters · filed 2015-05-14 | -$139.00K derived: sum of 3 quarters · filed 2015-05-14 | -$139.00K derived: sum of 4 quarters · filed 2015-05-14 |
| 2013-12-31 | -$139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | -$139.00K derived: sum of 2 quarters · filed 2015-03-31 | -$139.00K derived: sum of 3 quarters · filed 2015-03-31 | $0.00 10-K · filed 2015-03-31 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-01-08 | $0.00 derived: sum of 2 quarters · filed 2015-01-08 | $139.00K 10-Q · filed 2015-01-08 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-01-08 | $139.00K 10-Q · filed 2015-01-08 | ||
| 2013-03-31 | $139.00K 10-Q · filed 2015-01-08 | |||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-12-17 | $0.00 derived: sum of 2 quarters · filed 2014-12-17 | $0.00 10-Q · filed 2014-12-17 | |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-12 | $0.00 10-Q · filed 2014-12-12 | ||
| 2012-03-31 | $0.00 10-Q · filed 2014-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |